drugset / Trial / NCT00105937

OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

NCT00105937

Phase 3 Completed 300 enrolled Cephalon
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.

Timeline

Start
2004-04
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified

Indications